DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways^[1][2][3].

GLP-1/GIP^[1]

DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus^[1].
DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF)^[2].
DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson’s disease symptom potentially and enhances neurotransmission^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

4875.49

C₂₂₅H₃₄₆N₅₆O₆₅

2315504-40-4

Y-{aminoisobutyric acid}-EGTFTSDYSIYLDKQAA-{aminoisobutyric acid}-EFVNWLLAGGPSSGAPPPSKKKKKK-NH2

Room temperature in continental US; may vary elsewhere.

Protect from light, stored under nitrogen

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light, stored under nitrogen)

• [1]. Shi L, et al. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;327:65-74.

  [2]. Feng P, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2018;133:385-394.

  [3]. Li T, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson’s disease model. Life Sci. 2020;256:117824.